Previous close | 599.02 |
Open | 589.52 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 573.15 - 592.64 |
52-week range | 336.03 - 661.60 |
Volume | |
Avg. volume | 238 |
Market cap | 42.116B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | 58.84 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.41 (0.76%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.
Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth.
Lonza Group ( VTX:LONN ) Full Year 2023 Results Key Financial Results Revenue: CHF6.72b (up 7.9% from FY 2022). Net...